The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...

Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...

Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer ...

Chris Cotton is raising money for cancer centers after being told the day after his 50th birthday that what he thought was a ...

Bacillus Calmette-Guérin (BCG) remains the primary treatment for patients with high-risk bladder cancer, but resistance develops in 30% to 40% of cases. The use of oncolytic viruses has emerged as a ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the American Urological Association 2025 Annual ...

The "Gemcitabine Hydrochloride Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Gemcitabine ...

"CT can save lives, but its potential harms are often overlooked," said Dr. Rebecca Smith-Bindman, the study's lead author and a UCSF radiologist. Smith-Bindman, who also ...

New research has revealed that Schistosoma haematobium (S. haematobium), a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with ...

A new study found that an “often-overlooked” parasitic infection, already linked to bladder cancer, could also trigger cancer-related gene activity in the cervical lining. Even more troubling ...

most people put their attention toward prostate cancer or testicular cancer. What many people fail to realize is that another form—bladder cancer—is the fourth leading malignancy in men, far outpacing ...